Biogen Inc
BIIBHealthcare|Drug Manufacturers - General|USA
$172.34
-5.00 (-2.82%)
DCF (FCF)
$259.03
Tangible Book
$17.62
Graham Number
$77.87
Earnings Power
$149.79
About
Biogen is an established biopharmaceutical company focused on treatments for neurodegenerative and rare diseases. Its declining multiple sclerosis franchise is its largest revenue generator and contributed 40% of total revenue in 2025. Biogen also generates significant revenue from its CD20 collaboration agreements with Roche (19% of total in 2025), which includes oncology drugs Rituxan and Gazyva and multiple sclerosis drug Ocrevus. Biogen's newer franchises include Spinraza (spinal muscular atrophy, with partner Ionis), Leqembi (Alzheimer's disease, collabroation revenue from its partner Eisai), Skyclarys (Friedreich's ataxia, Reata), Zurzuvae (postpartum depression, Sage), and Qalsody (amyotrophic lateral sclerosis, Ionis).
Stock Price
+31.8%(1Y)
Pipeline Summary
515 total trials156
Phase 1
125
Phase 2
90
Phase 3
37
Phase 4
Completed: 364Terminated: 81Recruiting: 21Active: 17Unknown: 11Withdrawn: 13NOT_YET_RECRUITING: 4ENROLLING_BY_INVITATION: 2NO_LONGER_AVAILABLE: 1APPROVED_FOR_MARKETING: 1
Active Trials (38)
Study of an Intrathecal Port and Catheter System for Subjects With Spinal Muscular Atrophy
NCT05866419Spinal Muscular Atrophy
N/ARecruiting
Enrollment: 90 participants
A Study to Find Out How Nusinersen is Processed in the Body When Given Through the ThecaFlex DRx™ System in Adult and Pediatric Participants With Spinal Muscular Atrophy (PIERRE-PK)
NCT06555419Muscular Atrophy, Spinal
Phase 1Recruiting
Enrollment: 58 participants
PsoBest - The German Psoriasis Registry
NCT01848028Psoriasis
Recruiting
Enrollment: 3,500 participants
AHEAD 3-45 Study: A Study to Evaluate Efficacy and Safety of Treatment With Lecanemab in Participants With Preclinical Alzheimer's Disease and Elevated Amyloid and Also in Participants With Early Preclinical Alzheimer's Disease and Intermediate Amyloid
NCT04468659Preclinical Alzheimer's Disease
Phase 3Active
Enrollment: 1,400 participants
A Study to Confirm Safety and Efficacy of Lecanemab in Participants With Early Alzheimer's Disease
NCT03887455Early Alzheimer's Disease
Phase 3Active
Enrollment: 1,906 participants
BioScore
6.2/10
Watchlist
Ownership
Recent Insider Trades
Murphy NicoleBUY
2026-02-123 shares @ $195.04
Singhal PriyaSELL
2026-02-092,660 shares @ $199.83
Singhal PriyaSELL
2026-02-02748 shares @ $179.3
Singhal PriyaSELL
2025-09-02517 shares @ $133.55
Izzar RachidSELL
2025-07-082,223 shares @ $135
Recent News
2026-04-06 11:25:36
2026-04-02 11:00:39
2026-04-01 21:02:41
2026-04-01 18:00:28
2026-03-31 18:31:42
Data last updated: Apr 7, 2026, 03:35 AM